> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Covid-19 CGMP Adjustments
- URL: https://www.fdaweb.com/covid-19-cgmp-adjustments/
- Published: 2020-04-21T12:00:00.000Z
- Updated: 2026-09-14T16:12:02.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146615

BakerHostetler attorneys say that in this time of a Covid-19 pandemic, pharmaceutical companies should be making specific CGMP adjustments. “This includes conducting internal audits of CGMP compliance and increased scrutiny in specific areas that may relate to Covid-19,” the company says in an online [post](https://www.bakerlaw.com/alerts/fda-current-good-manufacturing-practice-inspections-during-the-covid-19-pandemic?ref=fdaweb.com).

As an example, it says that companies should consider training their employees on preventing the spread of disease and providing them regular updates on Covid-19 developments. “It may also be necessary to institute stricter protocols for hygiene, employee health, equipment sanitation, and even employee quarantines,” the post says.

“Despite last month’s FDA announcements to postpone most foreign facility inspections, the global pharmaceutical manufacturing industry should be prepared for heightened government scrutiny and an onslaught of FDA CGMP inspections as this crisis develops,” the attorneys write.

They say that during the pandemic agency inspections will likely focus on a facility’s sanitary conditions and the health and hygiene of the facility’s employees. “Pharmaceutical manufacturers, therefore, should thoroughly review policies regarding symptomatic presentations, potential Covid-19 infections, sterilization, and associated reporting,” the article says.